Comparative solution equilibrium and structural studies of half-sandwich ruthenium(II)(η6-toluene) complexes of picolinate derivatives by Poljarević, Jelena M. et al.
1 
 
Comparative solution equilibrium and structural studies of half-sandwich 
ruthenium(II)(6-toluene) complexes of picolinate derivatives 
   
Jelena M. Poljarević,a,b G. Tamás Gál,c Nóra V. May,c Gabriella Spengler,d Orsolya 
Dömötör,a Aleksandar R. Savić,b Sanja Grgurić-Šipka,b Éva A. Enyedya*  
 
a
 Department of Inorganic and Analytical Chemistry, University of Szeged, Dóm tér 7. H-6720 Szeged, Hungary 
b
 Faculty of Chemistry, University of Belgrade, Studentski trg 12-16, 11000 Belgrade, Serbia 
c
 Research Centre for Natural Sciences Hungarian Academy of Sciences, Magyar tudósok körútja 2, H-1117 
Budapest, Hungary 
d
 Department of Medical Microbiology and Immunobiology, University of Szeged, Dóm tér 10, H-6720 Szeged, 
Hungary 
 
Keywords: Stability constants; X-ray crystal structures; Half-sandwich complexes; Speciation; 
Antiproliferative activity  
 
* Corresponding author. 
E-mail address: enyedy@chem.u-szeged.hu (É.A. Enyedy). 
 
ABSTRACT 
Five Ru(II)(6-toluene) complexes formed with 2-picolinic acid and its various derivatives 
have been synthesized and characterized. X-ray structures of four complexes are also 
reported. Complex formation processes of [Ru(II)(6-toluene)(H2O)3]
2+
 organometallic cation 
with the metal-free ligands were studied in aqueous solution in the presence of chloride ions 
by the combined use of 
1
H NMR spectroscopy, UV-visible spectrophotometry and pH-
potentiometry. Solution stability, chloride ion affinity and lipophilicity of the complexes were 
characterized together with in vitro cytotoxic and antiproliferative activity in cancer cell lines 
being sensitive and resistant to classic chemotherapy and in normal cells as well. Formation of 
mono complexes such as [Ru(6-toluene)(L)(Z)]+/o (L: completely deprotonated ligand; Z = 
H2O/Cl
‒
) with high stability and [Ru(6-toluene)(L)(OH)] was found in solution. The pKa 
values (8.3-8.7) reflect the formation of low amount of mixed hydroxido species at pH 7.4 at 
0.2 M KCl ionic strength. The complexes are fairly hydrophilic and show moderate chloride 
ion affinity and fast chloride-water exchange processes. The studied complexes exhibit no 
cytotoxic activity in human cancer cells (IC50 > 100 M), only complexes formed with 2-
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picolinic acid (1) and its 3-methyl derivative (2) represented a moderate antiproliferative 
effect (IC50 = 84.8 (1), 79.2 μM (2)) on a multidrug resistant colon adenocarcinoma cell line 
revealing considerable multidrug resistant selectivity. Complexes 1 and 2 bind to human 
serum albumin covalently and relatively slowly with moderate strength at multiple binding 
sites without ligand cleavage.   
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1. Introduction 
  
 Ruthenium complexes have emerged as attractive alternatives to platinum based 
compounds such as cisplatin, carboplatin and oxaliplatin which are undoubtedly successful 
anticancer drugs but have several drawbacks such as serious side-effects and lack of activity 
against certain types of cancer. Ruthenium compounds have different physico-chemical and 
pharmacokinetic properties compared to the platinum drugs, and they have different 
mechanism of action as well, that is the reason why they are the subject of extensive drug 
discovery efforts [1-3]. Imidazolium trans-[tetrachlorido(DMSO)(imidazole)ruthenate(III)] 
(NAMI-A) was the first Ru(III) complex reached clinical trials [4], while sodium trans-
[tetrachloridobis(1H-indazole)ruthenate(III)] (NKP-1339, IT-139) is one of the most 
promising investigational non-Pt drugs in current clinical development. NKP-1339 is active 
against solid malignancies such as non-small cell lung cancer, colorectal carcinoma and the 
treatment is accompanied by minor side effects [5,6]. While cisplatin induces DNA damage 
via adduct formation [7], endoplasmic reticulum stress and reactive oxygen species-related 
effects were found to be involved in the mechanism of action of NKP-1339 [5,8]. Ru(III) 
complexes are considered as prodrugs that are activated by reduction and it provides the 
impetus for the development of various Ru(II) anticancer compounds [5]. It is noteworthy that 
a novel Ru(II) compound [Ru(4,4’-dimethyl-2,2’-bipyridine)2-(2-(2’,2’’:5’’,2’’’-
terthiophene)-imidazo[4,5-f][1,10]phenanthroline)]Cl2 (TLD-1433) has entered a human 
clinical trial recently as nontoxic photosensitizing agent [9]. Ru(II) is often stabilized in the 
+2 oxidation state by the coordination of η6-arene type ligands and there are two main 
prototypes of Ru(II)-arene complexes [3]: i) 1,3,5-triaza-7-phosphatricyclo-[3.3.1.1]decane 
(PTA) containing Ru(II)-arene (RAPTA) compounds such as [Ru(6-p-cymene)(PTA)Cl2] 
(RAPTA-C) possessing significant antimetastatic property and is ready for translation into 
clinical evaluation [10,11]; ii) the bidentate 1,2-ethylenediamine (en) containing Ru(II)-arene 
(RAED) complexes such as [Ru(6-biphenyl)(en)Cl]PF6 (RM175)  that possesses a similar 
cytotoxic activity to cisplatin [12,13]. In most of the half-sandwich organoruthenium(II) 
compounds a bidentate ligand with an (O,O), (O,S), (O,N), (N,N) or (N,S) binding mode is 
coordinated and a chloride ion acts as the leaving group [3,14-16]. Aquation (replacement of 
the chlorido ligand by a water molecule) facilitates the reaction with biological 
macromolecules such as proteins or DNA, therefore the strength of the Ru-Cl bond and the 
rate of its cleavage have a strong impact on the bioactivity of the Ru(II)-arene complexes 
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[17]. Notably, the chemical and pharmacological properties of the Ru(II)-arene half-sandwich 
compounds can be fine-tuned by variation of the coordinated ligand, the arene ring and the 
leaving group [1,3,10]. Although a large number of Ru(II)-arene compounds has been 
developed and extensively investigated, information about their solution speciation and 
stability constants is still limited in the literature. Most of the solution equilibrium studies are 
focused on [Ru(6-p-cymene)(X,Y)Cl] type complexes [18-24]. For the better understanding 
of the pharmacokinetic properties and mechanisms of action of these metal complexes, the 
knowledge of the aqueous chemistry and the most plausible chemical forms in water, 
especially at physiological pH, is a mandatory prerequisite.  
 In our previous works we have studied the biological activity of Ru(II)(6-p-cymene) 
complexes of various pyridine derivatives [25-28] and moderate-to-low cytotoxicity was 
found in six tumor cell lines; although the complex of pyridine-2-carboxylic acid (2-picolinic 
acid, picH) represents an enhanced antiproliferative activity (e.g. IC50 = 82 M in HeLa cells, 
36 M in FemX cells [27]) and antimetastatic effect based on wound migration assay [25]. 
The solution speciation of Ru(II)(6-p-cymene) picolinate complexes was also studied by 
some of us revealing the formation of mono-ligand complexes with high stabilities [23]. 
Notably, the Os(II) congener of the picolinate complex showed very high in vitro cytotoxic 
activity [29]. 
 As the physico-chemical and biological properties can be modified by the exchange of 
the arene ring, in this work we have prepared and structurally characterized Ru(II)(6-toluene) 
complexes formed with picH and its 3-methyl (3-Me-picH), 5-bromo (5-Br-picH), 4-
carboxylic (2,4-dipicH2) and 5-carboxylic (2,5-dipicH2) derivatives (Chart 1). In addition to 
the determination of the solid phase structures of four complexes by X-ray crystallography, 
solution speciation of these Ru(II)(6-toluene) complexes in water was revealed by UV-
visible (UV-vis) spectrophotometry, 
1
H NMR spectroscopy and pH-potentiometry involving 
studies on their stability and chloride ion affinity. The antiproliferative and cytotoxic 
effectiveness of these complexes in multidrug resistant/non-resistant human cancer lines was 
also tested. Interactions between human serum albumin and the complexes showing 
antiproliferative effect were monitored using fluorometry and ultrafiltration. 
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Chart 1. Chemical structures of the ligands in their completely deprotonated forms (a) and the general 
formula of the prepared [Ru(6-toluene)(L)(Cl)] complexes. 
 
2. Experimental 
 
2.1. Chemicals 
All solvents were of analytical grade and used without further purification. 2-Picolinic acid 
(picH), 3-methylpyridine-2-carboxylic acid (3-Me-picH), 5-bromo-2-pyridinecarboxylic acid 
(5-Br-picH), 2,4-pyridinedicarboxylic acid monohydrate (2,4-dipicH2·H2O), 2,5-
pyridinedicarboxylic acid (2,5-dipicH2), RuCl3·3H2O, KCl, HCl, KOH, 4,4-dimethyl-4-
silapentane-1-sulfonic acid (DSS), 1-methylimidazole (N-MeIm), human serum albumin 
(HSA, as lyophilized powder with fatty acids, A1653), NaClO4, KH2PO4, NaH2PO4·2H2O, 
Na2HPO4·2H2O were purchased from Sigma-Aldrich in puriss quality. Doubly distilled Milli-
Q water was used for preparation of samples. The purity of the ligands and the exact 
concentration of their stock solutions were determined by pH-potentiometric titrations and by 
the computer program Hyperquad2013 [30]. [Ru(η6-toluene)Cl2]2 was prepared according to a 
well known procedure [31]. A stock solution of [Ru(η6-toluene)(Z)3]
2+/+/o/‒
, where Z is H2O or 
Cl
‒
, was obtained by dissolving [Ru(η6-toluene)Cl2]2 in water and the exact concentration of 
this stock was determined with pH-potentiometric titrations. The modified phosphate-buffered 
saline (PBS’) contains 12 mM Na2HPO4, 3 mM KH2PO4, 1.5 mM KCl and 100.5 mM NaCl; 
and the concentration of the K
+
, Na
+
 and Cl
‒
 ions corresponds approximately to that of the 
human blood serum (c(K
+
) = 3.5-5.1 mM, c(Na
+
) = 135-145 mM, c(Cl
‒
) = 96-106 mM [32]). 
HSA solution was freshly prepared before the experiments and its concentration was 
estimated from its UV absorption: 280 nm(HSA) = 36850 M
−1
cm
−1
 [33]. Stock solution of N-
MeIm was prepared on a weight-in-volume basis in PBS’ solution. 
 
2.2. Synthesis of the complex [(η6-toluene)RuCl(μ-Cl)]2 with different picolinic acids 
N
O O-
N
O O-
Br
N
O O-
O O-
N
O O-
O
-O
N
O O-
pic 3-Me-pic        5-Br-pic             2,4-dipic         2,5-dipic       [Ru(6-toluene)(L)(Cl)]  
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O
6 
 
For the characterization of the prepared complexes 
1
H and 
13
C NMR spectroscopy, elemental 
analysis and electrospray ionization mass spectrometry (ESI-MS, Fig. S1) were used in 
addition to X-ray crystallography (vide infra). NMR spectra were recorded on a Bruker 
Avance III 500 spectrometer or a Bruker Ultrashield 500 Plus instrument, and DMSO-d6 was 
used as solvent. ESI-MS measurements were performed using a Micromass Q-TOF Premier 
(Waters MS Technologies) mass spectrometer equipped with electrospray ion source. 
Elemental analysis of all compounds was performed with a Perkin–Elmer 2400 CHN 
Elemental Analyser (Perkin–Elmer, Waltham, MA) at the Microanalytical Laboratory of the 
University of Vienna. 
 
2.2.1. Synthesis of the precursor [Ru(η6-toluene)Cl(μ-Cl)]2 
[Ru(η6-toluene)Cl(μ-Cl)]2 was prepared according the literature procedure used for the 
analogous [Ru(η6-benzene)Cl(μ-Cl)]2 [31] by adding 5 mL of 1-methyl-1,4-cyclohexadiene to 
a solution of 0.5 g RuCl3·3H2O (1.9 mmol) in 40 mL of absolute ethanol. This mixture was 
refluxed for 8 h. The reddish brown precipitate formed during the synthesis was filtered off, 
washed with diethyl ether and left to dry in exsiccator. Yield: 85%, 0.450 g; 
1
H NMR 
(500.26 MHz, DMSO-d6, , ppm): 2.12 (3H, s, CH3), 5.68 (3H, m, C2, C4, C6 toluene), 5.97 
(2H, m, C3, C5 toluene); 
13
C NMR (125.79 MHz MHz, DMSO-d6) 18.73 (CH3), 82.22 (C4 
toluene), 84.83 (C5, C3 toluene), 89.28 (C6, C2 toluene), 105.82 (C1 toluene). 
 
2.2.2. Synthesis of chlorido[(pyridine-κN-2-carboxylato-κO)(η6-toluene)ruthenium(II)] (1): 
A solution of picH (0.015 g, 0.13 mmol) in 2 mL of 2-propanol was added to a warm solution 
of [Ru(η6-toluene)Cl2]2 (0.030 g, 0.057 mmol) in 25 mL of 2-propanol. The reaction mixture 
was stirred at room temperature for 7 days and the yellow-range precipitate was formed. 
Solution was filtered off and product was dried in exsiccator. Yield: 58%, 0.023 g; 
1
H NMR 
(500.26 MHz, DMSO-d6, , ppm): 2.15 (3H, s, CH3), 5.60 (2H, m, C2, C6 toluene), 5.70 (1H, 
t, C4 toluene), 5.99 (2H, m, C3, C5 toluene), 7.71 (1H, dd, C5 ligand), 7.75 (1H, d, C3, 
ligand),  8.06 (1H, t, C4 ligand), 9.29 (1H, d, C6 ligand); 
13
C NMR (125.79 MHz, DMSO-d6) 
18.57 (CH3), 77.07 (C4 toluene), 78.44 (C5 toluene), 79.71 (C3 toluene), 86.15 (C6 toluene), 
88.06 (C2 toluene), 101.01 (C1 toluene), 125.31 (C3 ligand), 128.09 (C5 ligand), 139.64 (C4 
ligand), 150.89 (C2 ligand), 153.88 (C6 ligand). (Numbering of the ligand protons is shown in 
Chart S1.) ESI/MS (m/z) (Fig. S1): [M‒Cl]+ (C13H12NO2Ru, calculated: 315.9912) = 
315.9947 and [M‒Cl‒COO]+ (C12H12NRu, calculated: 272.0013) = 272.0025. Elemental 
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analysis: calculated for: C13H12O2NClRu (%): C, 44.51; H, 3.45; N, 3.99. Found (%): C, 
44.41; H, 3.37; N, 4.01. 
 
2.2.3. Synthesis of complexes of chlorido[(3-methylpyridine-κN-2-carboxylato-κO)(η6-
toluene)ruthenium(II)] (2), chlorido[(5-bromopyridine-κN-2-carboxylato-κO)(η6-
toluene)ruthenium(II)] (3), chlorido[(4-carboxylate-pyridine-κN-2-carboxylato-κO)(η6-
toluene)ruthenium(II)] (4), chlorido[(5-carboxylate-pyridine-κN-2-carboxylato-κO)(η6-
toluene)ruthenium(II)] (5): 
Methanolic solution of the ligand (3-Me-picH (10.4 mg, 0.076 mmol) or 5-Br-picH (15.4 mg, 
0.076 mmol) or 2,4-dipicH2·H2O (14.1 mg, 0.076 mmol) or 2,5-dipicH2 (12.7 mg, 0.076 
mmol)) was slowly added in the methanolic (5 mL) solution of [Ru(η6-p-toluene)Cl2]2 
(20.0 mg, 0.038 mmol) and reaction mixture was stirred for 3 h, at  40°C. Then, reaction 
volume was reduced to half and desired orange complex was precipitated. Solution was 
filtered off and product was dried in exsiccator. 
2: Yield: 57%, 0.016 g; 
1
H NMR (500.26 MHz, DMSO-d6, , ppm): 2.16 (3H, s, toluene 
CH3), 2.54 (3H, s, ligand CH3), 5.57 (1H, d,C2, toluene), 5.60 (1H, d, C6, toluene), 5.68 (1H, 
t, C4 toluene), 5.97 (2H, dd, C3, C5 toluene), 7.59 (1H, dd, C5 ligand), 7.89 (1H, d, C4 
ligand), 9.22 (1H, d, C6 ligand); 
13
C NMR (125.79 MHz, DMSO-d6) 18.37 (CH3, ligand), 
18.65 (CH3, toluene), 77.11 (C4 toluene), 78.88 (C5 toluene), 79.21 (C3 toluene), 86.62 (C6 
toluene), 88.43 (C2 toluene), 101.18 (C1 toluene), 126.88 (C5 ligand), 137.92 (C4 ligand), 
142.70 (C6 ligand), 147.29 (C3 ligand), 152.48 (C2 ligand), 170.89 (COO-Ru). ESI/MS (m/z) 
(Fig. S1): [M‒Cl]+ (C14H14NO2Ru, calculated: 330.0068) = 330.0079 and [M‒Cl‒COO]
+
 
(C13H14NRu, calculated: 286.0170) = 286.0176. Elemental analysis: calculated for: 
C14H14O2NClRu∙1.25H2O (%): C, 43.42; H, 4.29; N, 3.62. Found (%): C, 43.37; H, 4.08; N, 
3.68. 
3: Yield: 52%, 0.017 g; 
1
H NMR (500.26 MHz, DMSO-d6, , ppm): 2.17 (3H, s, CH3), 5.63 
and 5.67 (2H,dd ,C2, C6 toluene), 5.77 (1H, t,C4 toluene), 6.06 (2H, m, C3, C5 toluene), 7.68 
(1H, d, C3 ligand), 8.34 (1H, d, C4 ligand), 9.52 (1H, s, C6 ligand); 
13
C NMR (125.79 MHz, 
DMSO-d6) 18.41 (CH3), 76.98 (C4 toluene), 78.54 (C5 toluene), 79.21 (C3 toluene), 86.58 
(C6 toluene), 88.16 (C2 toluene), 101.60 (C1 toluene), 122.95 (C5 ligand), 126.30 (C3 
ligand), 142.28 (C4 ligand), 149.76 (C2 ligand), 154.04 (C6 ligand), 169.69 (COO-Ru). 
ESI/MS (m/z) (Fig. S1): [M‒Cl]+ (C13H11BrNO2Ru, calculated: 395.8996) = 395.9078 and 
[M‒Cl‒COO]+ (C12H11BrNRu, calculated: 351.9098) = 351.9121. Elemental analysis: 
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calculated for C13H11O2NBrClRu∙0.3H2O (%): C, 35.89; H, 2.69; N, 3.22. Found (%): C, 
35.90; H, 2.79; N, 2.96. 
4: Yield: 56%, 0.017 g; 
1
H NMR (500.26 MHz, DMSO-d6, , ppm): 2.18 (3H, s, CH3), 5.66 
(2H,dd ,C2, C6 toluene),5.75 (1H, t,C4 toluene), 6.06 (2H, m, C3, C5 toluene), 8.06 (2H, m, 
C3, C5 ligand), 9.51 (1H, d, C6 ligand), 14.22 (1H, s, free COOH ligand); 
13
C NMR (125.79 
MHz, DMSO-d6) 18.41 (CH3), 77.27 (C4 toluene), 78.94 (C5 toluene), 79.68 (C3 toluene), 
86.61 (C6 toluene), 88.17 (C2 toluene), 101.54 (C1 toluene), 123.82 (C3 ligand), 126.63 (C5 
ligand), 140.93 (C4 ligand), 151.88 (C6 ligand), 155.17 (C2 ligand), 164.66 (COO-Ru), 
169.73 (COOH). ESI/MS (m/z) (Fig. S1): [M‒Cl]+ (C14H12NO4Ru, calculated: 359.9810) = 
359.9876 and [M‒Cl‒COO]+ (C13H12NO2Ru, calculated: 315.9912) = 315.9947. Elemental 
analysis: calculated for C14H12O4NClRu∙0.5H2O (%): C, 41.64; H, 3.25; N, 3.47. Found (%): 
C, 41.64; H, 3.04; N, 3.52. 
5: Yield: 50%, 0.015 g; 
1
H NMR (500.26 MHz, DMSO-d6, , ppm): 2.18 (3H, s, CH3), 
5.66(1H, d ,C2 toluene), 5.70(1H, d, C6 toluene),5.80(1H, t, C4 toluene), 6.08 (2H, m, C3, C5 
toluene), 7.89 (1H, d, C3 ligand), 8.51 (1H, d, C4 ligand), 9.56 (1H, s, C6 ligand), 14.20 (1H, 
s, free COOH ligand); 
13
C NMR (125.79 MHz, DMSO-d6) 18.43 (CH3), 77.11 (C4 toluene), 
78.72 (C5 toluene), 79.32 (C3 toluene), 86.53 (C6 toluene), 87.99 (C2 toluene), 101.46 (C1 
toluene), 125.29 (C3 ligand), 130.63 (C4 ligand), 140.24 (C5 ligand), 153.28 (C6 ligand), 
154.32 (C2 ligand), 164.42 (COO-Ru), 169.56 (COOH). ESI/MS (m/z) (Fig. S1): [M‒Cl]+ 
(C14H12NO4Ru, calculated: 359.9810) = 359.9876 and [M‒Cl‒COO]
+
 (C13H12NO2Ru, 
calculated: 315.9912) = 315.9947. Elemental analysis: calculated for C14H12O4NClRu∙0.4H2O 
(%): C, 41.83; H, 3.21; N, 3.48. Found (%): C, 41.92; H, 3.05; N, 3.45. 
 
2.3. Crystallographic structure determination  
Single crystals, suitable for X-ray diffraction experiment, of compounds [Ru(6-
toluene)(pic)Cl] (1), [Ru(6-toluene)(3-Me-pic)Cl]∙H2O (2∙H2O), [Ru(
6
-toluene)(5-Br-
pic)Cl] (3) and [Ru(6-toluene)(2,5-dipic)Cl] (5)  were grown from methanol solution of the 
solid complexes.  
Orange (1) and yellow (2∙H2O, 3, 5) single crystals were mounted on loops and 
transferred to the goniometer. X-ray diffraction data were collected at ‒170 °C (for 1, 2∙H2O) 
or 20 °C (for 3, 5) on a Rigaku RAXIS-RAPID II diffractometer using Mo-K radiation. A 
numerical absorption correction [34] was carried out using the program CrystalClear [35]. 
Sir2014 [36] and SHELXL [37] under WinGX [38] software were used for structure solution 
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and refinement, respectively. The structures were solved by direct methods. The models were 
refined by full-matrix least squares on F
2
. Refinement of non-hydrogen atoms was carried out 
with anisotropic temperature factors. Hydrogen atoms were placed into geometric positions 
(except for water hydrogen atoms which were constrained). They were included in structure 
factor calculations but they were not refined. The isotropic displacement parameters of the 
hydrogen atoms were approximated from the U(eq) value of the atom they were bonded to. 
The summary of data collection and refinement parameters are collected in Table S1. Selected 
bond lengths and angles of compounds were calculated by PLATON software [39]. The 
graphical representation and the edition of CIF files were done by Mercury [40] and PublCif 
[41] softwares, respectively. The crystallographic data files for the complexes have been 
deposited with the Cambridge Crystallographic Database as CCDC 1574021-1574024.  
 
2.4. pH-potentiometric measurements and data evaluation 
The pH-potentiometric measurements determining the proton dissociation and formation 
constants were carried out at 25 ± 0.1°C and an ionic strength I = 0.20 M (KCl) in order to 
keep the activity coefficients constant. The titrations were performed with a carbonate-free 
KOH solution (0.20 M). The exact concentrations of HCl and KOH were determined by pH-
potentiometric titrations. An Orion 710A pH-meter equipped with a Metrohm combined 
electrode (type 6.0234.100) and Methrom 665 Dosimat burette were used for the pH-
potentiometric measurements. The volume resolution of the burette is 0.001 mL and its 
precision is 0.002 mL. The electrode system was calibrated to the pH = ‒ log[H+] scale by 
means of blank titrations (strong acid HCl vs. strong base KOH), as suggested by Irving et al. 
[42]. The average water ionization constant, pKw, was determined as 13.76 ± 0.01, which 
corresponds well to the literature data [43]. The reproducibility of the titration points included 
in the calculations was within 0.005 pH. The pH-potentiometric titrations were performed in 
the pH range 2.0 to 11.5. The initial volume of the samples was 5 mL. The ligand 
concentration was 2 mM and metal to ligand ratios of 1:1 and 1:2 were used. The samples 
were degassed by bubbling purified argon through them for 10 min prior the measurements 
and the argon was also passed over the solutions during the titrations.  
The computer program Hyperquad2013 [30] was utilized to establish the 
stoichiometry of the complexes and to calculate the overall stability constants. β(MpLqHr) is 
defined for the general equilibrium: 
pM + qL + rH ⇌ MpLqHr as β(MpLqHr) = [MpLqHr]/[M]
p
[L]
q
[H]
r
   (1) 
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where M denotes the metal moiety [Ru(η6-toluene)(Z)3] (Z = H2O/Cl
‒
) and L the completely 
deprotonated ligand. In all calculations exclusively titration data were used from experiments 
in which no precipitate was visible in the reaction mixture. The goodness-of-fit measured in 
Hyperquad2013 by sigma () represents the overall goodness-of-fit derived from the sum of 
squared residuals (calculated-experimental titration data). The model was accepted when  
was close to one (< 1.5). The standard deviation of the log values of species included into 
the model was always lower than 0.1. As equilibrium constants were determined in the 
presence of 0.20 M chloride ion, they are considered as conditional constants. log values for 
the various hydroxido complexes[(Ru(6-toluene))2(
2
-OH)i]
(4-i)+
 (i=2,3) were calculated 
based on the pH-potentiometric titration data in the presence of chloride ions and were found 
to be in fairly good agreement with previously published data [44].  
 
2.5. UV-vis spectrophotometric and 
1
H NMR spectroscopic titrations, and determination of 
the distribution coefficients 
A Hewlett Packard 8452A diode array spectrophotometer was used to record the UV-vis 
spectra in the interval 200 – 800 nm. The path length was 1 cm. Equilibrium constants (proton 
dissociation, stability constants and H2O/Cl
−
 exchange constants) and the individual spectra of 
the species were calculated with the computer program PSEQUAD [45]. The 
spectrophotometric titrations were performed in aqueous solution on samples containing the 
ligands with or without the organometallic cation, and the concentration of the ligands was 
100-120 μM. The organometallic cation was also titrated (120 M) separately. The metal-to-
ligand ratios were 1:1 in the pH range from 3 to 11.5 at 25.0±0.1 °C at an ionic strength of 
0.20 M (KCl). Measurements for 1:1 metal-to-ligand systems were also carried out by 
preparing individual samples in which KCl was partially or completely replaced by HCl; pH 
values, varying in the range ca.0.8–2.5, were calculated from the strong acid content. The 
absorbance data were recorded after various waiting time (1-48 h). UV-vis spectra recorded as 
a function of chloride concentrations (0–252 mM) were used to investigate the H2O/Cl
−
 
exchange processes of complexes [Ru(6-toluene)(L)(H2O)] at pH 5.5-7.0 (at a constant pH). 
In order to check the effect of the variable ionic strength on the logK’ (H2O/Cl
−
) constant in 
this titration experiment individual samples of complex 2 were also prepared in which a 
constant ionic strength was applied, namely the sum of concentrations of NaClO4 and NaCl 
was 0.30 M.    
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1
H NMR titrations were carried out on a Bruker Ultrashield 500 Plus instrument using 
WATERGATE water suppression pulse scheme. DSS was used as an internal NMR standard. 
1
H NMR spectra of samples containing [Ru(II)(η6-toluene)(H2O)3]
2+
 (1 mM) and ligand picH 
(1 mM) in D2O at various pH values were recorded after 4 h of incubation (25 °C, I = 0.20 M 
(KCl)). Titration of 2 mM solution of [Ru(η6-toluene)(Z)3] was also performed separately. To 
study the interaction with HSA and N-MeIm 
1
H NMR spectra were recorded for samples 
containing precursor [Ru(η6-toluene)Cl(μ-Cl)]2 or complex 1 (1 mM), with or without half 
equivalent of HSA or N-MeIm. Samples were prepared in PBSʹ buffer and incubated for 24 h 
at 25 °C. 
Distribution coefficients at physiological pH (D7.4) of the complexes 1–5 and the ligands 
as well as the Ru precursor were determined by the traditional shake-flask method in n-
octanol/buffered aqueous solution at pH 7.40 at various chloride concentrations using UV-vis 
detection as described in our former work [24]. 
 
2.6. Fluorescence and membrane ultrafiltration/UV-vis studies with HSA  
Fluorescence spectra were recorded on a Hitachi-F4500 fluorometer in 1 cm quartz cell at 
25.0 ± 0.1 °C. All solutions were prepared in PBS’ (pH 7.4) and were incubated for 24 h 
following a time-dependence experiment. Samples contained 1 M HSA, and various HSA-
to- Ru(6-toluene) or 1 or 2 ratios (from 1:0 to 1:10) were used. The excitation wavelength 
was 295 nm and the emission was read in the range of 310-500 nm. The quenching (KQ’) 
constants were calculated with the computer program PSEQUAD [45] using the same 
approach applied in our previous works [46,47]. 
Samples (0.50 mL) used for the ultrafiltration studies contained 40 M HSA and 
Ru(6-toluene) or 1 or 2  (up to 1:10 protein-to-complex ratio) in PBS’ buffer (pH 7.4) at 
25.0 ± 0.1 °C and were incubated for 24 h. Samples were separated by ultrafiltration through 
10 kDa membrane filters (Millipore Amicon Ultra-0.5 centrifugal filter unit) in low (LMM) 
and high molecular mass (HMM) fractions with the help of a temperature controlled 
centrifuge (Sanyo, 10000 rpm, 10 min). The LMM fraction containing the non-bound metal 
complex was separated from the protein and its adducts in the HMM fraction. The 
concentration of the non-bound compounds in the LMM fractions was determined by UV-vis 
spectrophotometry by comparing the recorded spectra to those of reference samples without 
the protein.  
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2.7. Cell lines 
Human colonic adenocarcinoma cell lines Colo 205 doxorubicin-sensitive (ATCC-CCL-222) 
and Colo 320/MDR-LRP multidrug resistant overexpressing ABCB1 (MDR1)-LRP (ATCC-
CCL-220.1) were purchased from LGC Promochem, Teddington, UK. The cells were cultured 
in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum, 2 mM L-
glutamine, 1 mM sodium pyruvate and 100 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES). The cell lines were incubated at 37 °C, in a 5% CO2, 
95% air atmosphere. The semi-adherent human colon cancer cells were detached with 
Trypsin-Versene (EDTA) solution for 5 min at 37 C.  
MRC-5 human embryonal lung fibroblast cell line (ATCC CCL-171) was purchased 
from LGC Promochem, Teddington, UK. The cell line was cultured in Eagle’s Minimal 
Essential Medium (EMEM, containing 4.5 g/L glucose) supplemented with a non-essential 
amino acid mixture, a selection of vitamins and 10% heat-inactivated fetal bovine serum. The 
cells were incubated at 37 °C, in a 5% CO2, 95% air atmosphere.  
 
2.8. Assay for cytotoxic effect 
In the study MRC-5 non-cancerous human embryonic lung fibroblast and human colonic 
adenocarcinoma cell lines (doxorubicin-sensitive Colo 205 and multidrug resistant Colo 320 
colonic adenocarcinoma cells) were used to determine the effect of compounds on cell 
growth. The effects of increasing concentrations of compounds (complexes 1-5, the metal-free 
ligands, the precursor [Ru(η6-toluene)Cl(μ-Cl)]2, and the positive control cis-[Pt(NH3)2(Cl)2]  
(cisplatin, Teva) on cell growth were tested in 96-well flat-bottomed microtiter plates. The 
compounds were diluted in a volume of 100 μL of medium. 
The adherent human embryonal lung fibroblast cells were cultured in 96-well flat-
bottomed microtiter plates, using EMEM supplemented with 10% heat-inactivated fetal 
bovine serum. The density of the cells was adjusted to 2×104 cells in 100 μL per well, the 
cells were seeded for 24 h at 37 C, 5% CO2, then the medium was removed from the plates 
containing the cells, and the dilutions of compounds previously made in a separate plate were 
added to the cells in 200 μL. 
In case of the colonic adenocarcinoma cells, the two-fold serial dilutions of 
compounds were prepared in 100 μL of RPMI 1640, horizontally. The semi-adherent colonic 
adenocarcinoma cells were treated with Trypsin-Versene (EDTA) solution. They were 
adjusted to a density of 2×104 cells in 100 μL of RPMI 1640 medium, and were added to each 
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well, with the exception of the medium control wells. The final volume of the wells 
containing compounds and cells was 200 μL.  
The culture plates were incubated at 37 °C for 24 h; at the end of the incubation 
period, 20 μL of MTT (thiazolyl blue tetrazolium bromide, Sigma-Aldrich) solution (from a 
stock solution of 5 mg/mL) were added to each well. After incubation at 37 °C for 4 h, 100 μL 
of sodium dodecyl sulphate (SDS) (Sigma-Aldrich) solution (10% in 0.01 M HCI) were 
added to each well and the plates were further incubated at 37 °C overnight. Cell growth was 
determined by measuring the optical density (OD) at 540/630 nm with Multiscan EX ELISA 
reader (Thermo Labsystems, Cheshire, WA, USA). Inhibition of the cell growth was 
determined according to the formula below: 
100100 








controlmediumODcontrolcellOD
controlmediumODsampleOD
 
Results are expressed in terms of IC50, defined as the inhibitory dose that reduces the growth 
of the cells exposed to the tested compounds by 50%.  
 
2.9. Assay for antiproliferative effect 
The method is similar to the one described in the assay described in Section 2.8 and 
antiproliferative effect of complexes 1-5, the metal-free ligands, the precursor [Ru(η6-
toluene)Cl(μ-Cl)]2 and cisplatin was determined. In the assay testing the inhibition of cell 
proliferation, 6×103 colon adenocarcinoma cells were distributed in 100 μL of medium with 
the exception of the medium control wells. The culture plates were incubated at 37 °C for 
72 h and after the incubation time the plates were stained with MTT according to the 
experimental protocol applied for the cytotoxicity assay vide supra. 
 
3. Results and discussion 
 
3.1. Synthesis, characterization and X-ray diffraction analysis of organometallic Ru(II) 
complexes  
The Ru(II) precursor [Ru(η6-toluene)Cl(μ-Cl)]2 and the complexes of picH, 3-Me-picH, 5-Br-
picH, 2,4-dipicH2 and 2,5-dipicH2 (Chart 1) were obtained according to the literature 
procedure used for the analogous Ru(η6-p-cymene) complexes [25-28]. Pure compounds (1-5) 
were isolated from methanol or 2-propanol with moderate yields 50-58%. The organometallic 
Ru(II) complexes were characterized by means of standard analytical methods (
1
H , 
13
C 
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NMR, elemental analysis and ESI-MS). The 
1
H NMR spectra of complexes confirm the 
coordination of the ligands manifesting itself in downfield or upfield shifts of the pyridine 
protons (e.g. in the case of 1 the C3 proton of the ligand is upfield while C4, C5 and C6 are 
downfield shifted upon coordination as shown in Fig. S2). The coordination of the pyridine 
nitrogen via its non-bonding electron pair results in a decrease of the electron density 
especially in the neighboring C6 proton. On the other hand the effect of the coordination of 
the carboxylate oxygen is reverse as the electron density is increased locally due to the 
negative charge decreasing the chemical shift of the nearest C3 proton compared to the case 
of the free ligand with the protonated COOH moiety. Similar observations were made for the 
analogous Ru(II)(6-p-cymene) complex of picH [27]. In general, signals representing 
protons next to the pyridine nitrogen were shifted distinctly upon coordination.  
Single crystals of complexes 1, 2∙H2O, 3 and 5 were obtained by the slow evaporation 
from methanol and their structures were determined by single crystal X-ray diffraction. The 
ORTEP representations of these complexes are depicted in Fig. 1. The complexes 1 and 2∙H2O 
crystallized in monoclinic crystal systems in space group P21/n and P21, respectively.  
 
Figure 1. Molecular structures of ruthenium complexes in crystal 1 (a) in crystal 2 (b) in crystal 3 and 
(c) in crystal 5 (d). Displacement parameters are drawn at 50% probability level; hydrogen atoms and 
water molecule for 2 are omitted for clarity. 
 
The crystals 3 and 5 crystallized in triclinic crystal systems in space group P-1. All of the 
complexes adopt the so-called “piano stool” configuration, whereby toluene forms the seat and 
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the chelating picolinate ligand as well as the chlorido leaving group constitute the chair legs. In 
these half-sandwich complexes the ligand is coordinated through the pyridine nitrogen and the 
carboxylate oxygen. In these structures Ru(II) is a chiral centre. In crystals 1, 3 and 5 both 
enantiomers were crystallized in non-chiral space groups. On the other hand complex 2 
crystallized together with a solvate water molecule and only one enantiomer could be found in 
the chiral space group P21. The absolute configuration RRu could be determined according to 
CIP convention [48], the Flack parameter is 0.01(5). The molecular structures of the studied 
complexes were directly compared to that of the benzene derivative [Ru(6-C6H6)(pic)(Cl)] 
defined previously (Ref. code OHUFUT [49]) which crystallized without solvate inclusion in 
triclinic P-1 space group (Fig. 2.) Selected bond distances and angles are collected in Table 1 
for comparison. Distances between the toluene ring and the Ru ion are within the range 
observed for other ruthenium arene half-sandwich complexes (2.079(11)-2.392(7) Å) [50]. 
Bond lengths and angles do not show significant differences compared to each other (data are 
within the experimental errors, Table 1). However, slight differences can be observed, namely 
the Ru-O bond length according to the influence of picolinate substituents. This bond length is 
increasing in the order of 2 < 1 ~ OHUFUT < 3 < 5 which is in agreement with the increasing 
electron-withdrawing effect the substituents in the order of -CH3 < -H < -Br < -COO
-
 group.  
 
 
Figure 2. Comparison of molecular structures of Ru(II)(η6-toluene) picolinate complexes 1 (colored 
by element), 2 (orange), 3 (yellow), 5 (violet) together with [Ru(6-C6H6)(pic)(Cl)] (CSD Ref. code 
OHUFUT) (cyan) [49].
 
Atoms Ru1, Cl1, N1 and O1 are superimposed.
 
 
However, the angles between planes of CgA and CgB (where Cg is the centre of gravity 
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calculated for rings A and B, respectively) show slight differences (Table 1 and Fig. 2). The 
methyl groups of the toluene molecule are almost in the same position for crystals 1, 2∙H2O 
and 3 (the torsion angle O1-Ru1-Cg(A)-C7 is 5.5
 o
, 13.3
o
  and -7.7
o 
degree for 1, 2∙H2O and 3, 
respectively). However, there is a significant difference in crystal 5 where the methyl group 
turns to the side of the chloride ion and this torsion angle is 116.2
o
). 
 
Table 1. Selected bond distances (Å) and angles (o) of the studied Ru(II)(η6-toluene) picolinate 
complexes in crystals 1-3, 5 and [Ru(6-C6H6)(pic)(Cl)] (OHUFUT [49]) 
 1 2∙H2O 3 5 OHUFUT 
Bond length (Å)      
Ru1-Cl1 2.4133(5) 2.415(2) 2.405(4) 2.396(3) 2.4133(6) 
Ru1-O1 2.074(1) 2.063(6) 2.085(9) 2.093(6) 2.075(2) 
Ru1-N1 2.089(2) 2.092(8) 2.11(1) 2.095(7) 2.087(2) 
Ru1-C1 2.183(2) 2.179(9) 2.17(1) 2.21(1) 2.178(3) 
Ru1-C2 2.194(2) 2.18(1) 2.23(1) 2.17(1) 2.179(3) 
Ru1-C3 2.185(2) 2.18(1) 2.16(1) 2.14(1) 2.191(3) 
Ru1-C4 2.187(2) 2.17(1) 2.16(1) 2.16(1) 2.190(3) 
Ru1-C5 2.148(2) 2.159(8) 2.21(1) 2.14(1) 2.168(3) 
Ru1-C6 2.174(2) 2.172(9) 2.16(1)  2.16(1) 2.160(3) 
Ru1-Cg(A) 
a
 1.6564(9) 1.656(4) 1.662(6) 1.659(5) 1.662 
Bond angles (
o
)      
O1-Ru1-N1 77.04(6) 76.8(3) 77.0(4) 77.4(3)  77.54(9) 
O1-Ru1-Cl1 87.44(4) 84.9(2) 85.9(3) 87.0(2) 87.04(6) 
N1-Ru1-Cl1 85.73(4) 83.7(2) 83.6(3) 84.2(2) 84.20(7) 
Cg(A)-Ru1-O1
 a
 127.69(5) 129.3(2) 129.6(4) 128.4(3) 128.77 
Cg(A)-Ru1-N1
 a
 132.73(5) 133.6(2) 134.2(4) 132.8(3) 132.55 
Cg(A)-Ru1-Cl1
 a
 128.74(4) 129.66(17) 128.2(2) 129.1(2) 128.97 
Cg(A)-Cg(B) 
b
 52.94(9) 64.1(5) 61.9(7) 58.9(6) 55.30 
O1-Ru1-Cg(A)-Cl1 5.5 13.3 -7.8 116.2 - 
a 
Cg is the centre of gravity calculated for ring A. 
b 
Angles between planes calculated for  
rings A and B. 
 
The positions of the picolinate ligands are slightly different in the studied complexes 
due to secondary interactions with adjacent molecules as different molecular arrangements and 
solvate inclusion (for crystal 2∙H2O) are encountered in these crystal structures. The packing 
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arrangements are shown in Figs. S3-S5 viewing along selected crystallographic axes. The main 
secondary interactions between molecules are C-H…O hydrogen bonds between the toluene 
hydrogens and the carboxylate oxygen (O1) of the picolinate ligand. Beside the hydrogen 
bonds considerable secondary interactions are formed between neighboring complexes by C-
H…Cl interactions (e.g. C12-H12…Cl1 in 2∙H2O and C5-H5…Cl1 in 4, Table S2 and Figs. S4 
and S6). 
 
3.2. Proton dissociation processes of the studied ligands and hydrolysis of the [Ru(6-
toluene)(H2O)3]
2+
 organometallic cation 
Proton dissociation constants of the ligands picH, 3-Me-picH, 5-Br-picH, 2,4-dipicH2 
and 2,5-dipicH2 (Chart 1) were determined by pH-potentiometric and UV-vis 
spectrophotometric titrations performed in the pH range from 2 up to 11.5 (Table 2). Molar 
absorbance spectra of the ligand species in the different protonation states were calculated via 
the deconvolution of the spectra recorded at various pH values as it is shown in Fig. S7 for 5-
Br-picH. The pKa value of picH and the calculated molar absorbance spectra of the HL and L
‒
 
forms are in reasonably good agreement with data reported previously [23,51,52]. The 
protonated compounds picH, 3-Me-picH, 5-Br-picH possess two, while 2,4-dipicH2 and 2,5-
dipicH2 have three dissociable protons. It was found in all cases that the first deprotonation 
step assigned to the carboxylic group at position 2 takes place in a fairly acidic range and no 
pKa values could be determined for this process. Therefore this carboxylate remains 
deprotonated in the whole studied pH range. pKa determined for picH, 3-Me-picH, 5-Br-picH 
can be attributed to the deprotonation of the pyridinium (NH
+
) group as well as the higher pKa 
of 2,4-dipicH2 and 2,5-dipicH2. The lower pKa of the latter two ligands belongs to the 
carboxylic group at position 4 and 5, respectively. Comparing the pKa values to that of Hpic, 
it is worth mentioning that the methyl substituent has no measurable effect at position 3, while 
the bromo and the carboxylic groups decrease the pKa (NH
+
) significantly due to the electron 
withdrawing power of the halogen substituent and the mesomeric effect of the COO
‒
 moiety. 
The pKa values of picH, 2,4-dipicH2 and 2,5-dipicH2 are in good agreement with data reported 
in the literature [53,54] (Table 2).   
Based on the determined pKa values it can be declared that all the studied ligands are 
present in their completely deprotonated forms (L
‒
: pic, 3-Me-pic, 5-Br-pic; L
2‒
: 2,4-dipic, 
2,5-dipic) at pH 7.4 resulting in their strongly hydrophilic character (logD7.4 < ‒2.5).    
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Table 2. Proton dissociation constants (pKa) of the studied ligands determined by pH-potentiometric 
and UV-vis spectrophotometric titrations; max and molar absorptivity () values for the ligand species 
in the different protonation states. {T = 25.0˚C, I = 0.20 M (KCl)} 
 Method pKa (COOH) pKa (NH
+
)  max (nm) /  (M
-1
cm
-1
) 
pic 
a
 pH-metry 
UV-vis 
< 1 
< 1 
5.13 ±0.03 
5.07 ±0.01 
 HL: 263 / 7100 
L
‒
: 263 / 3900 
3-Me-pic pH-metry 
UV-vis 
< 1 
< 1 
5.16 ±0.03 
5.16 ±0.03 
 HL: 274 / 6820 
L
‒
: 268 / 4400 
5-Br-pic pH-metry 
UV-vis 
< 1 
< 1 
3.44 ±0.02 
3.34 ±0.04 
 HL: 278 / 6570; 240 / 9770 
L
‒
: 268 / 4400; 232 / 10650 
2,4-dipic 
b
 pH-metry 
UV-vis 
1.84 ±0.05 
1.9 ±0.1 
4.70 ±0.02 
4.56 ±0.08 
 H2L: 278 / 5100 
HL
‒
: 274 / 5980 
L
2‒
: 276 / 3700 
2,5-dipic
 c
 pH-metry 
UV-vis 
2.19 ±0.05 
2.16 ±0.02 
4.63 ±0.04 
4.57 ±0.01 
 H2L: 272 / 6900 
HL
‒
: 272 / 7100 
L
2‒
: 272 / 5500 
a
 Reported pKa values for picH: 5.17 (NH
+
), ~1 (COOH) at I = 0.20 M (KCl), T = 25.0˚C in ref. [23];  5.19 
(NH
+
), ~1 (COOH) at I = 0.20 M (KCl), T = 25.0˚C in ref. [52]. b Reported pKa values for 2,4-dipic: 4.79 
(NH
+
), 2.23 (COOH) at I = 0.10 M (KNO3), T = 25.0˚C in ref. [53]. 
c
 Reported pKa values for 2,5-dipic: 
4.58 (NH
+
), 2.17 (COOH) at I = 0.50 M (NaClO4), T = 25.0˚C in ref. [54].   
 
Hydrolytic behavior of the organometallic cation [Ru(6-toluene)(H2O)3]
2+ 
has been 
already studied by Buglyó et al. in the presence and in the absence of chloride ions [44]. In 
the latter case the fast hydrolysis of the aquated organoruthenium cation yields the species 
[(Ru(6-toluene))2(μ
2
-OH)3]
+
 that becomes predominant at pH > 5. When 0.2 M KCl was 
used as the background electrolyte, as in our studies, formation of various chlorido and mixed 
chlorido/hydroxido species as intermediates was found in addition to the major hydrolysis 
product [(Ru(6-toluene))2(μ
2
-OH)3]
+
. In a good accordance with their findings based on the 
combined use of 
1
H NMR spectroscopy and ESI-MS, we have also detected three different 
species based on the 
1
H NMR spectra recorded at various pH values (Fig. S8). Namely, the 
identified species are [Ru(6-toluene)(H2O)2Cl]
+
 (= M), [(Ru(6-toluene))2(

-OH)2Cl]
+
 (= 
[M2(OH)2]) and [(Ru(
6
-toluene))2(

-OH)3]
+
 (= [M2(OH)3]). Overall stability constants for 
the dinuclear hydrolysis products [(Ru(6-toluene))2(
2
-OH)i]
(4-i)+
 (i = 2,3) were determined 
by pH-potentiometric and UV-vis spectrophotometric titrations at 0.20 M chloride ion 
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concentration (Table 3) and are in good agreement with data obtained by Buglyó et al. using 
pH-potentiometry [44]. Notably these are conditional stability constants being valid only at 
0.20 M KCl ionic strength. Concentration distribution curves were computed on the basis of 
the stability constants determined by pH-potentiometry showing that the hydrolysis is 
suppressed somewhat due to the presence of chloride ions, since [M2(OH)3] dominates only at 
pH > 6 (Fig. S9). The 
1
H NMR signals of the three kinds of species (M, [M2(OH)2], 
[M2(OH)3]) could be integrated and distribution of the organometallic fragment was 
calculated showing an acceptable match between the two kinds of methods. 
 
3.3. Complex formation equilibria of [Ru(6-toluene)(H2O)3]
2+
 with the picolinate ligands: 
stability, deprotonation, chloride ion affinity and lipophilicity 
Complexation processes were studied by the combined use of pH-potentiometric, UV-vis 
spectrophotometric titrations and 
1
H NMR spectroscopy in a 0.20 M chloride-containing 
medium. Therefore the formation (logK [ML]) and deprotonation (pKa [ML]) constants 
determined herein are considered as conditional stability constants. The complex formation 
between [Ru(6-toluene)(H2O)3]
2+
 and the studied bidentate picolinate ligands follows a fairly 
simple scheme (Chart S2). Namely a mono complex [Ru(6-toluene)(L)(Z)] (=[ML]) is 
formed, and a mixed hydroxido species [ML(OH)] appears by the deprotonation of the 
coordinated H2O molecule and/or by the displacement of the chlorido co-ligand by OH
‒
 in the 
basic pH range, similarly to the behavior of analogous half-sandwich Ru(6-p-cymene) 
complexes [22,23]. The complex formation of the organometallic cation with the picolinate 
ligands was found to be a rather slow process especially in the strongly acidic pH range. The 
steady state could be reached after ~4 h waiting time in the [Ru(6-toluene)(H2O)3]
2+
 ‒ 3-Me-
picH (1:1) system at pH 1.92 as the time-dependence of the UV-vis spectra indicates (Fig. 3). 
However, the complexation becomes faster at higher pH values and e.g. in the case of the 
picH the reaction was finished within 1 h at pH 2.79 (Fig. S10). Based on the recorded spectra 
it could be concluded that the complex formation proceeds in a great extent already at pH 2 in 
all cases. As a consequence logK [ML] constants were attempted to be determined from the 
UV-vis spectral changes of the metal-to-ligand charge-transfer (Ru 4d
6→π*) and ligand (π 
→π*) transition bands in the pH range from 0.8 to 2.5 (Table 2). Although in this pH range 
the complex formation is even slower, and the waiting time has a strong impact on the 
fraction of the complex formed (Fig. S11). It was found that at pH 0.86 in the [Ru(6-
toluene)(H2O)3]
2+
 ‒ 3-Me-picH system more than 15 h is needed to reach the constant 
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absorbance value (Fig. S12). Therefore 24 h waiting time was applied, however the 
measurements revealed only minor spectral changes (<5%) in this pH range in all the studied 
[Ru(6-toluene)(H2O)3]
2+
 – ligand systems. It indicates negligible decomposition of the 
complexes under such strongly acidic conditions. Thus for the logK [ML] constants only a 
lower limit could be estimated (Table 3). Based on these findings the complexation of picH 
with [Ru(6-p-cymene)(H2O)3]
2+
 was reinvestigated using longer incubation times (24 h) 
needed to reach steady state in the presence of chloride ions (0.2 M KCl) and a higher logK 
[ML] value (>10.7) was obtained than previously published [23].  
 
 
 
Figure 3. Time-dependence of UV-vis absorption spectra recorded for the [Ru(6-toluene)(H2O)3]
2+ ‒ 
3-Me-picH (1:1) system at pH = 1.92 in the presence of chloride ions. The inset shows the absorbance 
changes at 308 nm with fitted curve. {cRu = cL =123 M; T = 25 ˚C; I = 0.20 M (KCl); ℓ = 1.0 cm}. 
 
Table 3. Stability constants logK [ML], pKa [ML] values of the [Ru(
6
-toluene)(H2O)3]
2+
 complexes 
formed with picolinate ligands in 0.2 M chloride-containing aqueous solutions determined by various 
methods and estimated H2O/Cl
−
 exchange constants (logK’) for the [Ru(6-toluene)(L)(H2O)]
+
 
complexes. {T = 25.0 ˚C, I = 0.20 M (KCl)} a 
  logK [ML] pKa [ML] pKa [ML] logK’ (H2O/Cl
−
) 
ligand complex UV-vis UV-vis pH-metry UV-vis 
pic 1 >10.8 
b
 8.53 ±0.01 c 8.47 ±0.01 c 1.3 ±0.1 
3-Me-pic 2 >10.7 
b
 8.71 ±0.01 8.68 ±0.05 1.3 ±0.1 d 
5-Br-pic 3 > 9.1 
b
 8.47 ±0.01 8.41 ±0.03 1.5 ±0.1 
2,4-dipic 4 > 11.6 
b
 8.44 ±0.01 8.37 ±0.06 1.2 ±0.1 
2,5-dipic 5 > 11.9 
b
 8.58 ±0.01 8.38 ±0.07 1.1 ±0.1 
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a
 M denotes the organometallic fragment Ru(η6-toluene) that appears as [Ru(η6-toluene)(Z)3] (Z = H2O/Cl
‒
) 
in water in the presence of chloride ions. Hydrolysis products of the organometallic cation obtained in our 
work: log [M2(OH)2] = ‒6.32±0.05, log [M2(OH)3] = ‒10.58±0.02; and log [M2(OH)2] = ‒6.50, log 
[M2(OH)3] = ‒10.56 reported in ref. [44]. 
b
 Estimated values based on UV-vis spectrum recorded at pH 0.8; 
c
 
pKa [ML] values based on 
1
H NMR titrations: 8.52 ±0.09 (0.20 M KCl) and 7.87 ±0.09 (0 M KCl). d logK’ 
(H2O/Cl
‒
) = 1.19 ±0.06 determined at constant ionic strength (I = 0.30 M (NaClO4/NaCl)). 
 
Increasing the pH values the studied [ML] complexes may undergo deprotonation 
and/or decomposition. Deprotonation of the coordinated water molecule (and/or Cl
‒→ OH‒ 
exchange) results in the formation of mixed hydroxido [ML(OH)] complexes, while 
decomposition can yield unbound ligand and metal ion in hydrolyzed forms depending on the 
actual pH. The recorded UV-vis spectra were the same in a wide pH range (e.g. in the [Ru(6-
toluene)(H2O)3]
2+ ‒ 3-Me-picH system at pH between 3.1 and 7.6 shown in Fig. 4), while 
significant spectral changes are observed at pH > 8 due to the formation of [ML(OH)]. The 
appearance of isosbestic points suggests that the metal complexes do not decompose under 
these conditions; merely they are deprotonated almost in all cases. It should be noted that the 
complex of 5-Br-pic showed a low extent of decomposition in the basic pH-range. Based on 
these spectral changes pKa [ML] constants were determined for the complexes (Table 3). 
Notably, the spectra of the complexes did not change over a 24 h period at both pH 7.4 and 11 
values, and the deprotonation process was found to be rather fast. Therefore pH-
potentiometric titrations were also performed to determine pKa [ML] constants (Table 3) 
started from pH ~4 but only after a 4 h waiting period whilst the formation of [ML] becomes 
complete. pKa [ML] constants obtained by the two kinds of methods are in a good agreement.   
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Figure 4. UV-vis absorption spectra recorded for the [Ru(6-toluene)(H2O)3]
2+ ‒ 3-Me-picH (1:1) 
system in the presence of chloride ions in the pH range from 3 up to 11. The inset shows the 
absorbance changes at 306 nm at pH between 3.0 and 11.0. {cRu = 102 M; T = 25 ˚C; I = 0.20 M 
(KCl); ℓ = 1.0 cm}. 
 
In addition 
1
H NMR spectra were also recorded for the [Ru(6-toluene)(H2O)3]
2+
 – 
picH system at pH > 2.5 in the presence of 0.20 M chloride ions at a 1:1 metal-to-ligand ratio 
using 4 h incubation time (Fig. 5). The spectra undoubtedly reveal that neither free metal ion 
nor free ligand is present in the whole pH range studied (pH = 2.5 – 11.5), which means that 
the complex does not suffer from decomposition at 1 mM concentration due to its high 
stability. The aqua [ML(H2O)] and the chlorinated [ML(Cl)] complexes were identified in the 
acidic pH range. An upfield shift of all peaks belonging to the [ML(H2O)] complex is 
observed in the basic pH range due to the fast exchange process on the NMR time scale 
between the aquated and the mixed hydroxido [ML(OH)] species. In the meanwhile the 
intensity of the peaks belonging to the [ML(Cl)] complex is decreased. Based on the integrals 
of the CH(6) toluene proton in the acidic pH range we could conclude that the [ML] complex 
is mainly chlorinated (~83% [ML(Cl)]). As the [ML(OH)] starts to be formed the three 
species are present together in the solution, and their equilibrium concentrations cannot be 
simply calculated due to the fast exchange processes. 
Figure 5.
 1
H NMR spectra of [Ru(6-toluene)(H2O)3]
2+
 ‒ picH (1:1) system in aqueous solution in the 
presence of 0.2 M chloride ions at the indicated pH values in the regions of the ligand protons (a), the 
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toluene CH protons (b) and the toluene CH3 protons (c). {cRu = cL = 1 mM; T = 25 ˚C; I = 0.20 M 
(KCl); D2O; pH = pD×0.93+0.40 [55]}. 
 
Therefore, the pKa of the aqua [ML(H2O)] was determined (pKa = 7.87 ±0.09) based on the 
pH-dependent chemical shift (δ) values of [ML(H2O)] and [ML(OH)] species. (Notably this 
value equals to the pKa [ML] in the chloride-free medium.) Using this constant the ratio of the 
latter two species can be calculated at any chosen pH and then the actual concentrations of all 
the three complexes could be computed (Fig. 6). From the ratio of the summed concentration 
of [ML(Cl)] and [ML(H2O)]  (as [ML] species) and that of [ML(OH)] pKa [ML] in the 0.2 M 
chloride-containing medium was calculated (Table 3) representing a good match to the data 
obtained by the other two methods. 
 
  
Figure 6.
 
 Distribution of Ru(6-toluene) in the [Ru(6-toluene)(H2O)3]
2+
 ‒ picH (1:1) system in the 
presence of 0.2 M chloride ions in the pH range from 2.5 up to 11 based on the 
1
H NMR peak integrals 
for the CH(6) toluene proton of species identified based on Fig. 5. The ratio of the [ML(H2O)]
+
 and 
[ML(OH)] at a given pH is calculated using the pKa [ML] of the aqua complex. {cRu = cL = 1 mM; T = 
25 ˚C; I = 0.20 M (KCl)}. 
 
Since for the logK [ML] constants only minimum values could be obtained the direct 
comparison of the solution stability of these picolinate complexes is not possible. Comparing 
the stability constant of complex 1 to that of Rh(5-C5Me5) (logK [ML] = 9.18 [56]) it is 
found that the latter has at least 1.5 order of magnitude lower value. The logK [ML] constants 
of the studied Ru(6-toluene)-picolinate complexes indicate the formation of relatively high 
stability complexes suggesting that the decomposition is not higher than 1% and 15% for 
complexes 1 and 3 at pH 7.40, at 100 μM concentration, respectively. Based on the speciation 
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data it can be concluded that the complexes are present mainly in their [ML] forms at pH 7.4, 
and they are only partly deprotonated ([ML(OH)] ~ 10%) in the 0.20 M chloride-containing 
medium.  
The ratio of the chlorinated and aqua complexes ([ML(Cl)] and [ML(H2O)]) can be 
characterized by the H2O/Cl
‒
 exchange constant, which was estimated by UV-vis 
spectrophotometry using the same approach that we used in our previous works for analogous 
Rh(5-C5Me5) complexes [56,57]. Representative UV-vis spectra recorded at various chloride 
ion concentrations for the complex 1 and the measured and fitted absorbance values are 
shown in Fig. S13. Since in this titration experimental setup the ionic strength was not kept 
constant, individual samples of complex 2 were also prepared in which the summed 
concentration of NaCl and NaClO4 was a constant value (I = 0.30 M). The recorded spectra at 
the various chloride ion concentrations and the molar absorbance spectra of the aqua and 
chlorido complexes obtained by the two methods (Fig. S14) were fairly similar. The logK’ 
(H2O/Cl
−
) constant calculated by the batch technique was different by 0.1 logarithm unit from 
the one obtained by the titration. Although the effect of the variable ionic strength on the 
constant is small, the logK’ (H2O/Cl
−
) constants in Table 3 should be considered as estimated 
values. Notably a lower H2O/Cl
‒
 exchange constant allows an easier replacement of Cl
‒ 
by 
water or by donor atoms of biomolecules. The logK’ (H2O/Cl
−
) values (Table 3) obtained for 
1-5 reflect a moderate affinity towards chloride ions which is much weaker compared to the 
analogous Rh(5-C5Me5) picolinate complexes [56,57]. 
The dependence of cytotoxicity on chloride ion affinity has been reported for several 
Ru(η6-arene) complexes [58], however many other factors such as lipophilicity have a strong 
influence on the pharmacological activity. Therefore, distribution coefficients at pH 7.4 (D7.4) 
were determined for the complexes 1-5, for the metal-free ligands and for the precursor 
[Ru(η6-toluene)Cl(μ-Cl)]2 at various chloride ion concentrations according to the chloride 
content of blood serum: ~100 mM, cell plasma: ~24 mM and cell nucleus: ~4 mM. The 
precursor, the ligands, and the complexes 1, 4 and 5 were found to be very hydrophilic at each 
studied chloride ion concentration. Namely, these compounds were so preferentially 
distributed to water that the absorbance spectra of the aqueous phase before and after 
partitioning were almost identical. Therefore, using the n-octanol/water shake-flask method 
only a threshold limit could be estimated for the ligands, the precursor and complexes 1, 4 and 
5: logD7.4 < ‒2.5. logD7.4 values could be determined only for complexes 2 and 3 (Fig. 7), and 
they exhibit increasing lipophilicity with increasing chloride ion concentration, although even 
at 100 mM they are considered as fairly hydrophilic compounds. They have stronger 
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hydrophilic character in the presence of less chloride ions since they are more aquated and the  
complex turns to be charged ([ML(Cl)] → [ML(H2O)]
+
). 
 
Figure 7. n-Octanol/water distribution coefficients at pH 7.4 (logD7.4) for complexes 2 (white bars) 
and 3 (grey bars) at various chloride ion concentrations {T = 25 °C, pH = 7.4 (20 mM phosphate 
buffer)} 
 
3.4. Cytotoxic and antiproliferative activity in human cancer cell lines 
In order to evaluate the biological effects of complexes 1-5, antiproliferative and cytotoxicity 
assays were applied in doxorubicin-sensitive (Colo 205) and multidrug resistant (Colo 320) 
human colonic adenocarcinoma cell lines. The resistance of Colo 320 cells is primarily 
mediated by the overexpression of ABCB1 (P-glycoprotein), a member of the ATP-binding 
cassette (ABC) transporter family, which pumps out xenobiotics from the cells. Cytotoxicity 
was measured in normal human embryonal lung fibroblast cells (MRC-5) as well. In addition 
the corresponding free ligands and the precursor [Ru(η6-toluene)Cl(μ-Cl)]2 were tested for 
comparison. In case of the antiproliferative assay, a low cell number (6×103 cells/well) was 
chosen and the incubation period of the MTT assay was longer (72 h). Using these conditions 
the MTT assay provides information about the activity of the complexes to inhibit cell 
proliferation rather than growth inhibition. While in case of the high cell number 
(2×104 cells/well) used the MTT test characterizes more the effect of the compounds on the 
inhibition of cell growth and considered as a cytotoxicity assay. In the latter case an 
incubation time of 24 h was applied. In both assays cisplatin was used as a positive control. 
IC50 values are collected in Table S3. The ligands and the precursor did not show either 
cytotoxic or antiproliferative activities (IC50 >100 μM).  
The complexes 1-5 did not possess any cytotoxic activity on the colon 
adenocarcinoma cell lines and on the normal MRC-5 human embryonic fibroblast cells. On 
-2.5 -2 -1.5 -1 -0.5 0
logD7.4 of complexes 
4 mM
24 mM
100 mM
c (Cl-):
-1.4  0.2
-1.16  0.06
-0.97  0.04
-1.16  0.01
-1.60  0.07
-2.4  0.2
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the other hand the complexes 1 and 2 showed a moderate antiproliferative effect on the MDR 
Colo 320 colon adenocarcinoma cell line with IC50 values of 84.84 ± 4.79 and 79.19 ± 
6.71 μM, respectively. Interestingly, these complexes had greater activity on the MDR cell 
line than on the sensitive Colo 205 cell line implying the selectivity of these complexes 
towards the MDR colon adenocarcinoma cell line. 
Among the half-sandwich organometallic complexes of 2-picolinic acid reported in the 
literature [Os(6-p-cymene)(pic)Cl] has the highest cytotoxic effect [29], [Ru(6-p-
cymene)(pic)Cl] is moderately cytotoxic [27], while compounds [Ru(6-toluene)(pic)Cl] (1) 
and [Rh(5-C5Me5)(pic)Cl] [56] are not active (Table S4). However the IC50 values of these 
complexes were tested in different human cancer cells and cannot be compared directly, the 
remarkable cytotoxicity of the Os(II) complex is evident. Some basic physico-chemical 
properties (pKa [ML], logK’ (H2O/Cl
‒
), rate of chloride/water exchange) of these half-
sandwich compounds were collected in Table S4 to check whether the Os(II) complex has 
significantly distinct characteristics from the others. Unfortunately lipophilicity data are not 
available for the Os(II) and Ru(II) p-cymene complexes. The Os(II) complex has the lowest 
pKa [ML] and the highest chloride ion affinity among these complexes. A low pKa [ML] 
increases the chance for the formation of the ternary mixed hydroxido complex at pH 7.4 and 
[ML(OH)] is believed to be less prone to interact with biomolecules [59]. Thus, this 
difference of the Os(II) complex from the others most probably is not the reason for its higher 
bioactivity. The strong chloride ion affinity helps in retaining the original chlorido ligand 
coordinated in the blood serum and the neutral [ML(Cl)] picolinate complex can go across the 
cell membrane easier, that might be advantageous, but it makes the replacement of Cl
‒
 by 
water or donor atoms of proteins more difficult. Notably, the Os(II) complex shows 
significantly slower Cl
‒
/water co-ligand exchange process compared to the other compounds 
in addition to its slow ligand exchange processes [29], which might have a role in the 
bioactivity. In all we can conclude that the tested complex 1 exhibits some undoubtedly 
different physico-chemical properties compared to the active Os(II) analogue and it seems 
that its fast Cl
‒
/water exchange in addition to its strong hydrophilic character can be at least 
partly responsible for the lack of its cytotoxicity.         
   
3.5. Interaction of complexes 1 and 2 with human serum albumin 
HSA is the most abundant plasma protein and serves as a transport vehicle for a wide variety 
of endogenous compounds and pharmaceuticals. Binding to HSA has a strong impact on the 
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pharmacokinetic properties of drugs. This protein has various metal binding sites such as the 
N-terminal site, the reduced Cys34 residue, the multi-metal binding site and certain side chain 
donor atoms such as imidazole nitrogens of His are also able to coordinate to the metal ions 
[60,61]. On the other hand nonspecific binding pockets located in subdomains IIA and IIIA 
are willing to accommodate compounds of a wide variety [61]. In all diversified binding 
modes are possible for potential metallodrugs. 
Interaction of complexes 1 and 2 representing moderate antiproliferative activity (see 
Section 3.4) towards HSA was studied by mainly ultrafiltration/UV-vis and 
spectrofluorometric methods. All measurements were performed at pH 7.4 at 25 ºC using a 
modified phosphate buffered saline (PBS’) in which the concentration of the chloride ions 
corresponds to that of the human blood serum. First of all binding of 1 to HSA was monitored 
by 
1
H NMR spectroscopy. Spectra were recorded for 1 in the absence or in the presence of the 
protein after a 24 h incubation period (Fig. S15). (This incubation time was chosen as the 
preliminary time-dependence studies showed that the reaction is relatively slow, depending on 
the conditions several hours are needed to reach the equilibrium state.) It was found that the 
signal of the toluene methyl group is shifted in the presence of HSA and no free ligand was 
detected. These observations strongly suggest the formation of ternary adducts with the 
protein without ligand cleavage. Then the direct interaction of complexes 1, 2 and the [Ru(η6-
toluene)Cl(μ-Cl)]2 precursor was followed by ultrafiltration. The unbound, low molecular 
mass (LMM) fractions after separation were analyzed by UV-vis quantification. Analysis of 
the recorded spectra also suggested that the complexes 1, 2 are intact upon binding since we 
could not detect free ligand in the LMM fraction as the recorded normalized spectra were 
identical to the reference spectra (Fig. S16). Comparing the spectra recorded after the 
separation to reference spectra the ratio of the bound compounds per HSA was calculated and 
plotted against the ratio of the total concentrations of the complexes and the protein (Fig. 8).       
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Figure 8. Ratio of the bound complexes (Ru precursor, 1 and 2) and HSA plotted against the ratio of 
the total concentrations of the complexes and HSA calculated from the UV-vis spectra recorded for the 
LMM fractions of the ultrafiltered samples. {Original sample composition: HSA: 40 µM; complexes: 
40-400 µM; T = 25 ˚C; pH = 7.4 in PBS’; incubation time: 24 h}. 
 
These formation curves show the binding at multiple sites for the Ru precursor and for the 
complexes, although no saturation could be achieved up to the applied 10-fold complex 
excess. The binding of the precursor is almost quantitative, but realized at a lower level 
compared to the Rh(5-C5Me5) precursor [46]. The binding of 1 is somewhat weaker 
compared to 2; however at least 3 and 5 binding sites are feasible for them based on the 
formation curves (Fig. 8), respectively.    
 
 
Figure 9. Changes of fluorescence emission intensities at 338 nm plotted against the complex-to-HSA 
ratios for 1 (●), 2 (×) and the Ru precursor (▲) using 295 nm excitation wavelength. {cHSA = 1 µM; 
complexes: 0-10 µM; T = 25 ˚C; pH = 7.4 in PBS’; incubation time: 24 h}. 
 
 In order to obtain preliminary information about the binding sites the interaction of 1, 
2 and the Ru(II) precursor were monitored by fluorometry. HSA contains a single Trp (214) 
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residue near site I (at subdomain IIA) that is responsible for the majority of the intrinsic 
fluorescence of the protein. Upon excitation at 295 nm its emission can be attenuated by a 
binding event close to Trp214 [61,62]. It is worth mentioning that coordination of protein side 
chains such as histidine nitrogens (e.g. His242) [62] located nearby this site by the 
substitution of the chlorido/aqua ligand at the third coordination site of the Ru complex is 
very feasible. Addition of the Ru(II) compounds to HSA quenches the Trp214 fluorescence 
emission (Fig. 9) indicating that the conformation of the hydrophobic binding pocket is 
significantly affected upon their binding. Based on the emission intensity changes quenching 
constants were computed. LogKQʹ values of 5.25 ±0.01, 4.16 ±0.01 and 4.18 ±0.01 were 
obtained for the Ru precursor, 1 and 2, respectively. These values reflect fairly strong binding 
of the precursor, and a moderate and similar binding of 1 and 2 at this particular site of HSA. 
As more than one binding sites are suggested on the basis of the ultrafiltration measurements, 
the complexes 1 and 2 (as well as the precursor) should be bound on other sites beside site I as 
well, e.g. via the more accessible surface donors. Among the side chain donors His, Met and 
Cys residues are suggested to be responsible to coordinate to Ru complexes [63]. The 
prominent role of His was pointed out in the case of Rh(5-C5Me5) complexes in our former 
work [46]. Therefore interaction of 1 and the precursor with 1-methylimidazole (N-MeIm), a 
monodentate model compound of His, was screened by 
1
H NMR spectroscopy. It was found 
that 95% of the Ru(II) precursor is bound to N-MeIm at 1:1 ratio (Fig. S17), while 100% of 
the analogous [Rh(5-C5Me5)Cl(μ-Cl)]2 precursor is bound under the same condition [46]. In 
the case of complex 1 the original picolinate ligand was not replaced by the model compound 
but formation of ternary [Ru(η6-toluene)(pic)(N-MeIm)] complex of significant fraction (1: 
85%) was observed (Fig. S18). This observation confirms the feasible coordination of the 
imidazole nitrogen of His at the third coordination site of the studied picolinate complexes.    
 
4. Conclusions  
Metal complexes of 2-picolinic acid and its 3-methyl, 5-bromo, 4-carboxylic, 5-carboxylic 
derivatives formed with Ru(6-toluene) organometallic fragment were synthesized and 
characterized in solid phase and in solution. The structures of four complexes were  
determined by single-crystal X-ray diffraction showing a pseudo-octahedral “pianostool” 
geometry, and the deprotonated picolinates bind in a bidentate mode via (N,O) donor atoms 
and the coordination sphere is completed by a chlorido ligand. Complex formation 
equilibrium processes were studied in aqueous solution by the combined use of UV-visible 
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spectrophotometry, pH-potentiometry and 
1
H NMR spectroscopy in the presence of chloride 
ions in addition to the characterization of the proton dissociation equilibria of the ligands. The 
complex formation reached a significant extent already at pH 0.8 representing prominently 
high stability and was found to be slow; while deprotonation of the complex and 
water/chloride exchange processes took place fast. By means of these methods we could 
demonstrate exclusive formation of mono complexes such as [Ru(6-toluene)(L)(Z)]+/o (L: 
completely deprotonated ligand; Z = H2O/Cl
‒
) and [Ru(6-toluene)(L)(OH)] in solution. pKa 
values of 8.3-8.7 were obtained reflecting the formation of 5-10% mixed hydroxido species at 
pH 7.4 in the presence of 0.20 M KCl. The chloride ion affinity of the complexes was 
characterized by moderate H2O/Cl
−
 co-ligand exchange equilibrium constants (logK’ H2O/Cl
−
 
= 1.1-1.5) which are lower than those of the analogous Ru(6-p-cymene) and Rh(5-C5Me5) 
compounds.  
All the studied metal complexes exhibit a rather hydrophilic character at 100 mM 
chloride concentration and become even more hydrophilic at lower chloride content. The 
studied complexes were not cytotoxic against colon adenocarcinoma cell lines and normal 
MRC-5 human embryonic fibroblast cells. However, the complexes formed with 2-picolinic 
acid (1) and its 3-methyl derivative (2) represented a moderate antiproliferative effect (IC50 = 
84.84, 79.19 μM) on the multidrug resistant Colo 320 colon adenocarcinoma cell line 
revealing considerable MDR selectivity. Interaction of complexes 1 and 2 with the blood 
transport protein HSA was investigated by ultrafiltration and fluorometry. The binding is 
relatively slow and no ligand cleavage was observed, thus formation of ternary adducts with 
the protein via coordination bonds at several binding sites (at least 3-5) is suggested. Complex 
1 represents a somewhat weaker overall binding compared to 2, while their binding at site I is 
fairly similar based on the Trp(214) quenching studies. 1-methylimidazole binds efficiently to 
these complexes at the third coordination site suggesting the probable binding of imidazole 
nitrogens of the protein with non-dissociative characteristics.        
 
Abbreviations: 
5-Br-picH 5-bromo-2-pyridinecarboxylic acid 
cisplatin  cis-[Pt(NH3)2(Cl)2] 
D7.4 distribution coefficients at physiological pH 
2,4-dipicH2 2,4-pyridinedicarboxylic acid  
2,5-dipicH2 2,5-pyridinedicarboxylic acid 
DSS  4,4-dimethyl-4-silapentane-1-sulfonic acid 
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EMEM  Eagle’s Minimal Essential Medium 
en 1,2-ethylenediamine 
HMM high molecular mass 
HSA human serum albumin 
LMM low molecular mass 
MDR multidrug resistance  
3-Me-picH 3-methylpyridine-2-carboxylic acid 
MTT 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide 
NAMI-A trans-[tetrachlorido(DMSO)(imidazole)ruthenate(III)] 
NKP-1339 sodium trans-[Ru(III)Cl4(Ind)2], Ind = indazole; IT-139 
N-MeIm 1-methylimidazole 
PBS’ modified phosphate-buffered saline 
picH  pyridine-2-carboxylic acid, 2-picolinic acid 
PTA 1,3,5-triaza-7-phosphatricyclo-[3.3.1.1]decane 
RAED 1,2-ethylenediamine containing Ru(II)-arene 
RAPTA 1,3,5-triaza-7-phosphatricyclo-[3.3.1.1]decane containing Ru(II)-arene 
RAPTA-C  [Ru(6-p-cymene)(PTA)Cl2] 
TLD-1433 [Ru(4,4’-dimethyl-2,2’-bipyridine)2-(2-(2’,2’’:5’’,2’’’-terthiophene)-imidazo[4,5-
f][1,10]phenanthroline)]Cl2 
UV-vis UV-visible  
 
Acknowledgements 
This work was supported by National Research, Development and Innovation Office-NKFIA through 
projects GINOP-2.3.2-15-2016-00038, FK 124240, K 115762, the UNKP-17-4 New National 
Excellence Program of the Ministry of Human Capacities (E.A.E. and O.D.), the J. Bolyai Research 
Scholarship of the Hungarian Academy of Sciences (N.V.M.) and Ministry of Education, Science and 
Technological development – Republic of Serbia (MPNTR 172035 and MPNTR postdoctoral grant (J. 
M. P.)). The authors thank to Prof. Vladimir B. Arion (University of Vienna) for the elementary 
analysis of the complexes.  
 
Appendix A. Supplementary data 
Supplementary data associated with this article can be found online at… 
 
References 
 
32 
 
[1] G.N. Kaluderovic, R. Paschke, Curr. Med. Chem. 18 (2011) 4738–4752. 
[2] M.A. Jakupec, M. Galanski, V.B. Arion, C.G. Hartinger, B.K. Keppler, Dalton Trans. 
(2008) 183–194. 
[3] L. Zeng, P. Gupta, Y. Chen, E. Wang, L. Ji, H. Chao, Z-S. Chen, Chem. Soc. Rev. 46 
(2017) 5771–5804. 
[4] E. Alessio, Eur. J. Inorg. Chem. 2017 (2017) 1549–1560. 
[5] R. Trondl, P. Heffeter, C.R. Kowol, M.A. Jakupec, W. Bergerbd, B.K. Keppler, Chem. 
Sci. 5 (2014) 2925–2932. 
[6] H.A. Burris, S. Bakewell, J. Bendell, J. Infante, S. Jones, D. Spigel, G.J. Weiss, R.K. 
Ramanathan, A. Ogden, D. Von Hoff, ESMO Open, 1 (2017) e000154. 
[7] Y. Jung, S.J. Lippard, Chem. Rev. 107 (2007) 1387–1407. 
[8] B. Schoenhacker-Alte, T. Mohr, C. Pirker, K. Kryeziu, P.S. Kuhn, A. Buck, T. 
Hofmann, C. Gerner, G. Hermann, G. Koellensperger, B.K. Keppler, W. Berger, P. 
Heffeter, Cancer Lett. 404 (2017) 79–88. 
[9] https://clinicaltrials.gov/ct2/show/NCT03053635?term=tld-1433&recrs=a&rank=1. 
Accessed on 25/09/2017 
[10] B.S. Murray, M.V. Babak, C.G. Hartinger, P.J. Dyson, Coord. Chem. Rev. 306 (2016) 
86–114. 
[11] A. Weiss, R. H. Berndsen, M. Dubois, C. Müller, R. Schibli, A. W. Griffioen, P. J. 
Dyson, P. Nowak-Sliwinska, Chem. Sci. 5 (2014) 4742–4748. 
[12] R.E. Morris, R.E. Aird, P.D. Murdoch, H.M. Chen, J. Cummings, N.D. Hughes, S. 
Parsons, A. Parkin, G. Boyd, D.I. Jodrell, P.J. Sadler, J. Med. Chem. 44 (2001) 3616–
3621. 
[13] R.L. Hayward, Q.C. Schornagel, R. Tente, J.C. Macpherson, R.E. Aird, S. Guichard, A. 
Habtemariam, P. Sadler, D.I. Jodrell, Cancer Chemother. Pharmacol. 55 (2005) 577–
583. 
[14] W.H. Ang, A. Casini, G. Sava, P.J. Dyson, J. Org. Chem. 696 (2011) 989–998. 
[15] B. Therrien, Coord. Chem. Rev. 253 (2009) 493–519. 
[16] S.H. van Rijt, P.J. Sadler, Drug Discov. Today 14 (2009) 1089–1097. 
[17] A. Merlino, Coord. Chem. Rev. 326 (2016) 111–134. 
[18] L. Bíró, E. Farkas, P. Buglyó, Dalton Trans. 39 (2010) 10272–10278.  
[19] L. Bíró, E. Balogh, P. Buglyó, J. Organomet. Chem. 734 (2013) 61–68. 
[20] D. Hüse, L. Bíró, J. Patalenszki, A.C. Bényei, P. Buglyó, Eur. J. Inorg. Chem. 2014 
(2014) 5204–5216. 
33 
 
[21] Z. Bihari, Z. Nagy, P. Buglyó, J. Organomet. Chem. 782 (2015) 82–88. 
[22] É.A. Enyedy, É. Sija, T. Jakusch, C.G. Hartinger, W. Kandioller, B.K. Keppler, T. Kiss, 
J. Inorg. Biochem. 127 (2013) 161–168. 
[23] É. Sija, C.G. Hartinger, B.K. Keppler, T. Kiss, É.A. Enyedy, Polyhedron 67 (2014) 51–
58. 
[24] O. Dömötör, V.F.S. Pape, N.V. Nagy, G. Szakács, E.A. Enyedy, Dalton Trans. 46 
(2017) 4382–4396. 
[25] N. Gligorijević, S. Arandelović, L. Filipović, K. Jakovljević, R. Janković, S. Grgurić-
Šipka, I. Ivanović, S. Radulović, Z.Lj, Tešić, J. Inorg. Biochem. 108 (2012) 53–61. 
[26] S. Grgurić-Šipka, I. Ivanović, G. Rakić, N. Todorović, N. Gligorijević, S. Radulović, 
V.B. Arion, B.K. Keppler, Eur. J. Med. Chem. 45 (2010) 1051–1058. 
[27] I. Ivanović, S. Grgurić-Šipka, N. Gligorijević, S. Radulović, A. Roller, Z.Lj. Tešić, B.K. 
Keppler, J. Serb. Chem. Soc. 76 (2011) 53–61. 
[28] I. Ivanović, K.K. Jovanović, N. Gligorijević, S. Radulović, V.B. Arion, K.S.A.M. 
Sheweshein, Z.Lj. Tesic, S. Grgurić-Šipka, J. Organomet. Chem. 749 (2014) 343–349. 
[29] A.F.A. Peacock, S. Parsons, P.J. Sadler, J. Am. Chem. Soc. 129 (2007), 3348–3357. 
[30] P. Gans, A. Sabatini, A. Vacca, Talanta 43 (1996) 1739–1753. 
[31] R.A. Zelonka, M.C. Baird, Can. J. Chem. 50 (1972) 3063–3072. 
[32] C. Lentner, Geigy Scientific Tables, Vol. 3; West-Caldwell, NJ: Ciba-Geigy, 1984. 
[33] G.H. Beaven, S. Chen, A. D'Albis, W.B. Gratzer, Eur. J. Biochem. 42 (1974) 539–546. 
[34] T.Higashi, Numerical Absorption Correction, NUMABS (2002) 
[35] CrystalClear SM 1.4.0 Rigaku/MSC Inc. (2008) 
[36] M.C. Burla, R. Caliandro, B. Carrozzini, G.L. Cascarano, C. Cuocci, C. Giacovazzo, M. 
Mallamo, A. Mazzone, G. Polidori, J. Appl. Crystallogr. 48 (2015) 306–309. 
[37] SHELXL-2013 Program for Crystal Structure Solution, University of Göttingen, 
Germany (2013) 
[38] L.J. Farrugia, J. Appl. Crystallogr. 45 (2012) 849–854. 
[39] A.L. Spek, J. Appl. Crystallogr. 36 (2003) 7–13. 
[40] C.F. Macrae, P.R. Edgington, P. McCabe, E. Pidcock, G.P. Shields, R. Taylor, M. 
Towler, J. van De Streek, J. Appl. Crystallogr. 39 (2006) 453–457. 
[41] S.P. Westrip, J. Appl. Crystallogr. 43 (2010) 920–925. 
[42] H.M. Irving, M.G. Miles, L.D. Pettit, Anal. Chim. Acta 38 (1967) 475–488. 
[43] SCQuery, The IUPAC Stability Constants Database, Academic Software (Version 5.5), 
R. Soc. Chem., 1993–2005. 
34 
 
[44] L. Bíró, A.J. Godó, Z. Bihari, E. Garribba, P. Buglyó, Eur. J. Inorg. Chem. 2013 (2013) 
3090–3100. 
[45] L. Zékány, I. Nagypál, in: Computational Methods for the Determination of Stability 
Constants (Ed.: D.L. Leggett), Plenum Press, New York, 1985, pp. 291–353 
[46] É.A. Enyedy, J.P. Mészáros, O. Dömötör, C.M. Hackl, A. Roller, B.K. Keppler, W. 
Kandioller, J. Inorg. Biochem. 152 (2015) 93–103. 
[47] O. Dömötör, C.G. Hartinger, A.K. Bytzek, T. Kiss, B.K. Keppler, E.A. Enyedy, J. Biol. 
Inorg. Chem. 18 (2013) 9–17. 
[48] R.S. Cahn, C. Ingold, V. Prelog, Angew. Chem., Int. Ed. Engl. 5 (1966) 385–415. 
[49] K.D. Camm, A. El-Sokkary, A.L. Gott, P.G. Stockley, T. Belyaeva, P.C. McGowan, 
Dalton Trans. (2009) 10914–10925. 
[50] W.S. Sheldrick, S. Heeb, Inorg. Chim. Acta 168 (1990) 93–100. 
[51] É.A. Enyedy, D. Hollender, T. Kiss, J. Pharm. Biomed. Anal. 54 (2011) 1073–1081. 
[52] T. Jakusch, K. Gajda-Schrantz, Y. Adachi, H. Sakurai, T. Kiss, L. Horváth, J. Inorg. 
Biochem. 100 (2006) 1521‒1526. 
[53] M. Yasuda, K. Yamasaki, Naturwissenschaften 45 (1958) 84‒84. 
[54] A. Napoli, J. Inorg. Nucl. Chem. 32 (1970) 1907‒1913. 
[55] K. Ősz, G. Lente, C. Kállay, J. Phys. Chem. B 109 (2005) 1039‒1047. 
[56] É.A. Enyedy, O. Dömötör, C.M. Hackl, A. Roller, M.S. Novak, M.A. Jakupec, B.K. 
Keppler, W. Kandioller, J. Coord. Chem. 68 (2015) 1583–1601. 
[57] O. Dömötör, C.M. Hackl, K. Bali, A. Roller, M. Hejl, M.A. Jakupec, B.K. Keppler, W. 
Kandioller, E.A. Enyedy, J. Organomet. Chem. 846 (2017) 287–295. 
[58] Y.K. Yan, M. Melchart, A. Habtemariam, P.J. Sadler, Chem. Commun. (2005) 4764–
4776. 
[59] F. Wang, H. Chen, S. Parsons, I.D.H. Oswald, J.E. Davidson, P.J. Sadler, Chem. Eur. J. 
9 (2003) 5810–5820. 
[60] W. Bal, M. Sokołowska, E. Kurowska, P. Faller, Biochim. Biophys. Acta 1830 (2013) 
5444–5455. 
[61] G. Fanali, A. Masi, V. Trezza, M. Marino, M. Fasano, P. Ascenzi, Mol. Asp. Med. 33 
(2012) 209–290. 
[62] T. Peters, All About Albumin: Biochemistry, Genetics and Medical Applications, 
Academic Press, San Diego, 1996 
[63] W. Hu, Q. Luo, X. Ma, K. Wu, J. Liu, Y. Chen, S. Xiong, J. Wang, P.J. Sadler, F. 
Wang, Chem. Eur. J. 15 (2009) 6586–6594. 
